Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 6/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128100 | 0.85 | PIN1 (0.39) | TRPM8PIN1TRPV4CCR1ACKR3 | |
| SCHEMBL13872662 | 0.79 | TRPV4 (0.52) | TRPV4TACR2 | |
| SCHEMBL4139891 | 0.78 | BMP1 (0.39) | TRPV4CCR1ACKR3 | |
| SCHEMBL4136152 | 0.77 | BMP1 (0.39) | TRPV4CCR1CYP3A4CYP2C19 | |
| SCHEMBL4136278 | 0.75 | BMP1 (0.39) | TRPV4CCR1CYP3A4CYP2C19LPAR2 | |
| SCHEMBL4139617 | 0.74 | TRPV4 (0.48) | PIN1TRPV4OPRM1TACR2 | |
| SCHEMBL14606010 | 0.73 | RAB9A (0.47) | TRPV4CCR1ACKR3OPRM1HDAC3 | |
| SCHEMBL4135447 | 0.72 | TRPV4 (0.57) | PIN1TRPV4OPRM1TACR2 | |
| SCHEMBL5435367 | 0.72 | BMP1 (0.40) | TRPV4CCR1CYP3A4CYP2C19 | |
| SCHEMBL4136338 | 0.71 | TRPV4 (0.54) | PIN1TRPV4OPRM1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | TRPM8 12/4885PIN1 978/4885TRPV4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.